No Data
CICC: Maintain CMS "Outperform Industry" rating with a Target Price of 11.00 HKD.
CICC released a Research Report stating that it maintains its profit forecast for CMS (00867) without change, with the company's stock currently trading at 10.8 times / 9.7 times adjusted PE for 2025/2026, maintaining an outperform rating and a Target Price of 11.00 HKD, corresponding to 14.6 times / 13.1 times adjusted PE for 2025/2026. On the evening of April 22, the company announced a proposal to spin off its subsidiary Demei Pharmaceutical for independent listing on the Main Board of the Hong Kong Stock Exchange. The spin-off proposal is still subject to approval from relevant authorities, the company's Board of Directors, and the Board of Directors of Demei Pharmaceutical.
Major rating | Daiwa: The high trading volume of Hong Kong stocks driven by unclear market factors is unlikely to be sustained, lowering the Target Price of the Hong Kong Stock Exchange to HKD 394.
Dahua Jixian published a research report stating that driven by the AI boom in China, the daily average trading volume has shown strong performance, and it is expected that HKEX (0388.HK) will see a 36.3% year-on-year increase in net profit for the first quarter of this year. Although the trading volume surged after the impact of US tariffs, it is believed that the high trading speed driven by market uncertainties is unlikely to sustain. It is expected that as risk-off sentiment spreads, the daily average trading volume will gradually slow down. After the recent drop in stock prices, the firm noted that HKEX's valuation is not particularly expensive. Considering the market data so far this year and the revised forecast for the daily average trading volume, they have raised HKEX's earnings estimate for 2025 by 4.2%, but the lower...
Hong Kong's SFC Secures Legislative Approval for 2026 Launch Uncertificated Securities Regime
The only representative from Hong Kong! Bonnie Chan Yi-ting from the Hong Kong Stock Exchange (00388) has been selected as one of the Global 100 most influential people.
On April 16, 2025, USA's Times magazine released the list of the "100 Most Influential People in the Global World."
Citi: Cuts the Target Price of HKEX to HKD 385 and lowers profit forecasts for FY2026 and FY2027.
Citi released a research report stating that it expects HKEX (00388) to have a profit attributable to shareholders of 3.9 billion HKD in the first quarter of the fiscal year 2025, growing 3% and 31% quarter-on-quarter and year-on-year, respectively; total revenue is expected to reach 6.7 billion HKD, which represents growth of 5% and 29% quarter-on-quarter and year-on-year, mainly benefiting from the surge in the average daily trading volume (ADT) of Hong Kong stocks. Additionally, Citi raised its earnings per share forecast for HKEX in the fiscal year 2025 by 1%; however, it lowered the forecasts for the fiscal years 2026 and 2027 by 2% to 3%. The bank adjusted its target price for HKEX from 410 HKD to 385 HKD, maintaining a 'Buy' rating. The bank indicated that due to the unresolved issues in Hong Kong.
HKEX (00388.HK): Forfeiture of unclaimed second interim dividend for the year 2018.
On April 15, Gelonghui reported that HKEX (00388.HK) announced that on February 28, 2025, according to the HKEX Articles of Association, the second interim dividend of 3.07 Hong Kong dollars per share for the year 2018, which was declared on April 15, 2019, and remains unclaimed as of April 15, 2025, will be forfeited and returned to HKEX. Therefore, the total unclaimed second interim dividend for the year 2018, amounting to 15,493,077.70 Hong Kong dollars, has been forfeited and returned to HKEX today.
